Trials / Completed
CompletedNCT01469793
A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
A Phase I, Open Label Study of the Safety and Pharmacokinetics of Escalating Doses of DMOT4039A in Patients With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This multicenter, open-label, dose-escalating study will assess the safety, tolerability, and pharmacokinetics of DMOT4039A in participants with unresectable pancreatic or platinum-resistant ovarian cancer. Cohorts of participants will receive multiple ascending intravenous doses of DMOT4039A.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DMOT4039A | DMOT4093A will be administered by intravenous infusion on either a Q3W or a Q1W dosing schedule, in 21-day cycles. |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2011-11-10
- Last updated
- 2017-01-10
Locations
6 sites across 2 countries: United States, Netherlands
Source: ClinicalTrials.gov record NCT01469793. Inclusion in this directory is not an endorsement.